‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...
The Globe and Mail13d
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
A patient would only need a single treatment. CRISPR-Cas9 is comprised of two parts. A guide RNA will target the specific sequence within the genome, and Cas9 will be used as the molecular ...
pharmaphorum5d
Bayer and CRISPR Therapeutics launch gene drug discovery venture
Bayer is just the latest in a string of big pharma companies to invest in firms with CRISPR-Cas9 expertise ... on "game-changing or possibly curative treatments" for serious human genetic diseases.
Seeking Alpha16d
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...
AZoLifeSciences on MSN8d
Synthetic Biology and the Next Generation of Microbiota-Based Therapies
Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...
Phys.org24d
Scientists engineer CRISPR enzymes that evade immune system
Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...